Kurzfassung

A Randomized, double-blind, placebo-controlled, multicenter, exploratory evaluation of surrogate markers of cardiovascular risk in patients with active chronic plaque-type psoriasis treated for up to 52 weeks with subcutaneous (s.c.) secukinumab (300 mg or 150 mg)